AXSM

128.7475.11%
RA

Roger A. Jeffs

CEO & Director

Dr. Roger A. Jeffs, Ph.D., serves as Director at Liquidia Corporation (formerly known as Liquidia Technologies, Inc.) since November 2020 and serves as its Chief Executive Officer from January 3, 2022. He serves as Co-Founder and Vice Chairman at Kriya Therapeutics, Inc, where he has served since October 2019. He has been Senior Advisor of United Therapeutics Corporation since June 21, 2016. He is The Co-Founder and Co-Owner of Bull City Select Investments, An Investment Firm Focused on In-Licensing and Development of Early-Stage Biotechnology Assets. He served as a Director of RareGen, LLC from August 2018 until November 2020. Dr. Jeffs is the Vice-Chairman and co-founder of Kryia Therapeutics. He has rich experience in the biopharmaceutical industry in R&D, clinical development, regulatory and medical affairs. He served as a Co-Chief Executive Officer of United Therapeutics Corporation from January 1, 2015 to June 26, 2016 and its President from April 2001 to June 26, 2016, Chief Operating Officer from April 2001 to December 31, 2014 and Vice President of Research, Development and Medical since July 2000. He joined United Therapeutics Corporation in September 1998 as Director of Research, Development and Medical. While at United Therapeutics, he led the clinical development, regulatory approval and commercialization of six rare disease products. He worked for United Therapeutics Corporation. Previously, he served as The Worldwide Clinical Leader of The Infectious Disease Program at Amgen Inc. and as a Member of The Clinical Research Team at Burroughs Wellcome & Company, where he held roles in clinical development. Prior to 1998, he worked at Amgen, Inc. as Manager of Clinical Affairs and Associate Director of Clinical Research from 1995 to 1998. He had been a Member of Strategic Advisory Board at Pluristem Therapeutics Inc. since March 26, 2018 until February 2022. He served as a Director of Albireo Pharma, Inc. since September 28, 2017 until January 03, 2022. He served as a Director of Dova Pharmaceuticals, Inc. since May 2017 until November 12, 2019. He served as a Director of Sangamo Therapeutics, Inc. since June 2017 until June 11, 2019. He has been Director of Spyryx Biosciences, Inc. since January 16, 2018. He has been Independent Director of Axsome Therapeutics, Inc. since December 2014 and served as its Lead Director. He served as Director of United Therapeutics Corporation from 2002 to June 21, 2016. He served as Director of Axovant Gene Therapies Ltd. from February 12, 2018 to August 16, 2019. He holds a BS/BA degree in Chemistry from Duke University and PhD in Pharmacology from University of North Carolina School of Medicine.

Positions